Characterizing mechanisms of resistance to BRAF and MEK inhibitors in cancers with Class 2 BRAF mutations: uncovering novel therapeutic opportunities von Riaud, M., Biondini, M., Cianfarano, E., Rousselle, E., Maxwell, J., Soria-Bretones, I., Tai, P., Wang, H., Siegel, P.M., Cescon, D.W., Spreafico, A., Rose, A.A.N.

Volltext